Skak K - Search Results

1

The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy.

Eriksen KW, Søndergaard H, Woetmann A, Krejsgaard T, Skak K, Geisler C, Wasik MA, Odum N. Eriksen KW, et al. Among authors: skak k. Mol Immunol. 2009 Feb;46(5):812-20. doi: 10.1016/j.molimm.2008.09.006. Epub 2008 Oct 22. Mol Immunol. 2009. PMID: 18947877

2

IL-21: roles in immunopathology and cancer therapy.

Søndergaard H, Skak K. Søndergaard H, et al. Among authors: skak k. Tissue Antigens. 2009 Dec;74(6):467-79. doi: 10.1111/j.1399-0039.2009.01382.x. Epub 2009 Oct 21. Tissue Antigens. 2009. PMID: 19845910 Review.

3

Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.

Søndergaard H, Frederiksen KS, Thygesen P, Galsgaard ED, Skak K, Kristjansen PE, Odum N, Kragh M. Søndergaard H, et al. Among authors: skak k. Cancer Immunol Immunother. 2007 Sep;56(9):1417-28. doi: 10.1007/s00262-007-0285-4. Epub 2007 Feb 7. Cancer Immunol Immunother. 2007. PMID: 17285290 Free PMC article.

4

Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.

Søndergaard H, Coquet JM, Uldrich AP, McLaughlin N, Godfrey DI, Sivakumar PV, Skak K, Smyth MJ. Søndergaard H, et al. Among authors: skak k. J Immunol. 2009 Dec 1;183(11):7326-36. doi: 10.4049/jimmunol.0902697. Epub 2009 Nov 13. J Immunol. 2009. PMID: 19915059

5

Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.

Søndergaard H, Galsgaard ED, Bartholomaeussen M, Straten PT, Odum N, Skak K. Søndergaard H, et al. Among authors: skak k. J Immunother. 2010 Apr;33(3):236-49. doi: 10.1097/CJI.0b013e3181c0c1cb. J Immunother. 2010. PMID: 20445344

6

Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression.

Skov S, Rieneck K, Bovin LF, Skak K, Tomra S, Michelsen BK, Ødum N. Skov S, et al. Among authors: skak k. Blood. 2003 Feb 15;101(4):1430-8. doi: 10.1182/blood-2002-07-2073. Epub 2002 Oct 17. Blood. 2003. PMID: 12393479 Free article.

7

In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics.

Skak K, Søndergaard H, Frederiksen KS, Ehrnrooth E. Skak K, et al. Cytokine. 2009 Dec;48(3):231-8. doi: 10.1016/j.cyto.2009.07.039. Epub 2009 Aug 25. Cytokine. 2009. PMID: 19709902

8

Interleukin-21 activates human natural killer cells and modulates their surface receptor expression.

Skak K, Frederiksen KS, Lundsgaard D. Skak K, et al. Immunology. 2008 Apr;123(4):575-83. doi: 10.1111/j.1365-2567.2007.02730.x. Epub 2007 Nov 14. Immunology. 2008. PMID: 18005035 Free PMC article.

9

IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma.

Frederiksen KS, Lundsgaard D, Freeman JA, Hughes SD, Holm TL, Skrumsager BK, Petri A, Hansen LT, McArthur GA, Davis ID, Skak K. Frederiksen KS, et al. Among authors: skak k. Cancer Immunol Immunother. 2008 Oct;57(10):1439-49. doi: 10.1007/s00262-008-0479-4. Epub 2008 Feb 20. Cancer Immunol Immunother. 2008. PMID: 18286285 Free PMC article. Clinical Trial.

10

Interleukin 21: combination strategies for cancer therapy.

Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV. Skak K, et al. Nat Rev Drug Discov. 2008 Mar;7(3):231-40. doi: 10.1038/nrd2482. Nat Rev Drug Discov. 2008. PMID: 18259184 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters